PolyPid (PYPD)
(Delayed Data from NSDQ)
$4.75 USD
-0.05 (-1.12%)
Updated Apr 26, 2024 03:43 PM ET
After-Market: $4.89 +0.14 (2.89%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.75 USD
-0.05 (-1.12%)
Updated Apr 26, 2024 03:43 PM ET
After-Market: $4.89 +0.14 (2.89%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
PolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
PolyPid Ltd. (PYPD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Think PolyPid Ltd. (PYPD) Could Surge 206%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for PolyPid Ltd. (PYPD) points to a 205.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is Liquidia Technologies (LQDA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Liquidia Technologies, Inc. (LQDA) and PolyPid Ltd. (PYPD) have performed compared to their sector so far this year.
All You Need to Know About PolyPid Ltd. (PYPD) Rating Upgrade to Buy
by Zacks Equity Research
PolyPid Ltd. (PYPD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Believe PolyPid Ltd. (PYPD) Could Rally 223%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for PolyPid Ltd. (PYPD) points to a 222.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Think PolyPid Ltd. (PYPD) Could Surge 289%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for PolyPid Ltd. (PYPD) points to a 288.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Does PolyPid Ltd. (PYPD) Have the Potential to Rally 166% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 165.8% in PolyPid Ltd. (PYPD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.